Phenotypic frailty in people living with HIV is not correlated with age or immunosenescence

Stephen A. Klotz1, Cesar Egurrola1, Maria Love2, Mary N. Miller1, Nicole Bradley2, Shannon N. Smith1, Bijan Najafi3 and Nafees Ahmad2

Abstract
Background: It has been hypothesized that HIV-1 infection prematurely “ages” individuals phenotypically and immunologically. We measured phenotypic frailty and immune “aging” markers on T-cells of people living with HIV on long term, suppressive anti-retroviral therapy (ART) to determine if there is an association between frailty and immunosenescence.
Methods: Thirty-seven (37) community-dwelling people living with HIV were measured for frailty using a sensor-based frailty meter that quantifies weakness, slowness, rigidity, and exhaustion. An immunological profile of the patients’ CD4+ and CD8+ T-cell expression of cell surface proteins and cytokines was performed (n = 20).
Results: Phenotypic frailty prevalence was 19% (7/37) and correlated weakly with the number of past medical events accrued by the patient (r = 0.34, p = .04). There was no correlation of frailty with age, sex, prior AIDS diagnosis or HIV-1 viral load, or IFN-γ expression by CD4+ or CD8+ T-cells. There were more immune competent (CD28+ CD57−) cells than exhausted/senescent (CD28− CD57+) T-cells.
Conclusion: Frailty in people living with HIV on long term, suppressive ART did not correlate with aging or T cell markers of exhaustion or immunosenescence.

Keywords
HIV, frailty, immunosenescence, anti-retroviral therapy, immune restoration

Date received: 1 November 2021; revised: 5 February 2022; accepted: 14 March 2022

Introduction
In the 1980s and ‘90s, the physical manifestations of untreated HIV-1 infection and the side effects of anti-retroviral therapy (ART) were common and obvious to all clinicians. For example, weight loss, cutaneous Kaposi’s sarcoma, lipodystrophy, and neuropathy were commonplace. One hypothesis advanced to explain the physical deterioration in people living with HIV was that the HIV-1 virus aged the patient “with an earlier occurrence of a phenotype that resembles the phenotype of frailty in older adults without HIV infection”.2 Another hypothesis claimed that HIV/AIDS “compr[ess] the aging process, perhaps accelerating comorbidities and frailty.”3 The implication was that HIV-1 infection, particularly when untreated, leads to premature aging and frailty. This concept still has adherents today4 although we have shown that ART actually reverses some of these processes.5

It is a fact that untreated HIV-1 infection is associated with the onset of a frail phenotype in some individuals. In the current era when therapy is advocated for all patients, therefore, it is important to establish whether ART prevents, ameliorates, or reverses frailty and immunosenescence. The irreversible loss of physical function over time can be portrayed as a spiral of decreased mobility and activity leading to the pre-frail state and finally, frailty.6 Untreated HIV-1 infection also leads to immunosenescence with the accumulation of CD8+ and CD4+ T-cell subsets associated

1 Department of Medicine, University of Arizona Medical Center - University Campus, Tucson, AZ, USA
2 Department of Immunology, College of Medicine, University of Arizona, Tucson, AZ, USA
3 AZ and Department of Surgery, Baylor College of Medicine, Houston, TX, USA

Corresponding author:
Stephen A. Klotz, Department of Medicine, University of Arizona Medical Center - University Campus, 1501 N. Campbell Ave, Tucson, AZ 85724, USA.
Email: sklotz@u.arizona.edu
with aging. For example, terminally differentiated CD28⁻/CD57⁺ bearing T-cells found in untreated HIV-positive patients are the hallmark of immunosenescence, whereas, the loss of naïve CD4⁺ and CD8⁺ T-cells demonstrates an ineffective response to the HIV-1 infection. In aging uninfected individuals, there is a major decline in CD4⁺ and CD8⁺ cells expressing CD28, in itself an expression of immunosenescence.

In this work, we measure physical frailty as well as immunological markers of aging in a group of older, mostly men, on long-term, suppressive ART. Our goal was to determine if there is some association of frailty or immunosenescence in people living with HIV on long term ART. Several markers of inflammation have been studied with regard to their contribution to aging and frailty such as CRP and IL-6 and others have looked at socioeconomic factors. However, we chose immunological markers of aging in people living with HIV, comparing markers in nonfrail with frail individuals living with HIV. We wondered if frailty was correlated or perhaps, causally linked to immunosenescence. We found that prolonged, suppressive ART restores many immunological parameters previously damaged by HIV, even returning some immunological measurements to normal values. Although HIV targets the immune system and clearly contributes to frailty, both processes, frailty and immunosenescence appear to be reversible.

**Methods**

**Demographics**

Our large urban HIV clinic serves the surrounding metropolitan area of Tucson and southern Arizona (approximately 1800 patients). The same physician (SAK) has followed these patients for over 20 years and >91% are virally suppressed (meaning <200 copies of HIV-1 RNA). Some subjects participated in previous aging/frailty studies. For this study we recruited patients who were compliant with ART, of an older age, virally suppressed for years, and who consented to cell harvesting for our studies of immunological aging. Recruits were not chosen on the basis of frailty as that was measured later. It is important to note that frailty was determined within a year of cell surface analysis. The study was approved by the Institutional Review Board of the University of Arizona, Tucson, Arizona. Informed consent was obtained from all participants, and the study performed in accordance with relevant guidelines and regulations approved by the University of Arizona Biosafety Committee. Baseline demographic and medical information was collected at the time of frailty measurement and included age, sex, occurrence of specific, past medical events (heart disease, lung disease, neurological disease, arthritis, cancer, and surgery) resulting in hospitalization for two or more days in the last year or at any time in the past, the last CD4⁺ count, last viral load value, and whether the patient had been previously diagnosed with AIDS. These data are available from a dedicated EMR system accessed by the investigators.

**Frailty measurements**

Measurement of frailty were performed using a sensor-based upper extremity method called Frailty Meter (FM) (Frailty Meter™, Biosensics, Newton, MA). FM consists of one wrist-worn sensor and a wirelessly connected tablet. FM works by quantifying weakness, slowness, rigidity, and exhaustion during a 20-second repetitive elbow flexion/extension task using the wrist-worn sensor. The four scores indicate how different aspects of the patient’s performance contribute to their frailty and generate a frailty index score (FI) ranging from zero to one; higher values indicate progressively greater severity of frailty. Twenty (20) seconds was chosen from a prior study in which a 20-second repetitive elbow flexion/extension exercise was long enough to capture alterations in elbow angular velocity due to the presence of exhaustion phenotype (based upon the Fried Frailty Exhaustion phenotype), but not too long to observe a noticeable alteration in those without the presence of exhaustion phenotype. Using a machine learning model, the measured phenotypes are mapped into a continuous FI scale ranging from 0 to 1. This methodology has been validated against Fried criteria which serve as the “gold standard” of the phenotypic measurement of frailty and which we performed in all prior frailty investigations. The sensor is attached to a tablet which provides a rapid readout of the results. We measured the FI using the dominant and non-dominant hand as well as a dual task exercise which entailed counting backward from 100 in increments of three while performing the elbow flexion with the dominant hand. In a previous study, it was demonstrated that dual-task exercise allows distinguishing between older adults with and without cognitive impairment. An FI over 0.27 indicates that the patient is frail.

**Measurement of Depression**

We measured all subjects for the presence of depression using the Center for Epidemiological Studies-Depression (CES-D) test. CES-D is a quick 20 question test developed to detect depression. A score ≥22 indicates the possibility of major depression; scores between 15 and 21 suggests moderate to mild depression; score <15 indicates no depression present in the patient.

**Immunology and other clinical data**

Blood samples were drawn from patients following permission and processed at the University of Arizona Repository Laboratory. Peripheral blood mononuclear cells
were cryopreserved for future analysis. A complete blood count was performed using an Ac-T 5diff CP machine (Beckman Coulter, Pasadena, CA). Cryopreserved PBMC (1–2x10⁶/sample) were stained with LIVE/DEAD Fixable Dead Cell Stain-AQUA (Invitrogen) and T cell markers in various combinations. The following mAbs were used to differentiate T cell subsets: CD3—BV570 (BioLegend), CD4—APC (eBioscience), CD8β—ECD (Beckman Coulter), CD95—BV421 (BioLegend), CD28—PerCp/Cy5.5 (BioLegend), CCR7—FITC (BD Pharmingen), CD45RA—BV605 (BioLegend), CD57—BV570 (BioLegend), IFN-γ—APC e780 (eBioscience). Cells following various combination and incubations as described in our previous study, were analyzed on the BD LSR II instrument using DiVa acquisition (BDIS, Mountain View, CA) and the FlowJo analysis software (TreeStar Inc., Ashland, OR).

Twenty (20) of 37 patients in this study completed the entire cell surface analysis.

Statistical analysis: frailty analysis

A Pearson’s correlation coefficient and corresponding p-value were constructed for FI and CES-D scores against each clinical factor: age, last CD4⁺ cell count, number of past medical events; binary variables were sex, past medical event, AIDS diagnosis, and if virally suppressed (<200 copies/mL). Correlations greater than 0.8 or less than −0.8 indicate a strong linear relationship between the outcome and predictor and p-values less than 0.05 are considered statistically significant. All correlations and p-values were calculated in SAS version 9.4.

Immunologic analysis

Cell population totals were graphed using median values with 95% confidence intervals. An unpaired, non-parametric Mann–Whitney test was used to determine statistical significance between different populations. A linear regression model was used for all linear plots comparing a population of CD4 and CD8 T-cell counts and FI or age. Statistical significance was obtained by comparing the slope of the population to a slope of zero. In the event both linear regression slopes were significantly non-zero, the slopes were compared to each other to determine if they were significantly different. Software used was GraphPad Prism version 7. The following cells and surface markers were investigated: total CD4 and CD8 cell counts/percentages; CD4 CD28, CD4 CD57, CD4 CD28 CD57, and CD8 CD28, CD8 CD57, CD8 CD28 CD57, and CD4 and CD8 production of IFN-γ (PHA-stimulated and unstimulated), and CD8 TNF-α (PHA-stimulated and unstimulated).

Figure 1. (a)CD4 and CD8 T-cell counts and the Frailty Index measuring the dominant hand. The difference in the two cell populations was not significant: p = .3754; there was no significant correlation between Frailty Index and CD4 cell count, r = 0.00030, or CD8 cell count, r = 0.02144. (b) CD8⁺ CD28 cells and the Frailty Index measuring the dominant hand. *The difference in the two cell populations was significant: p = 0.0430; there was no significant correlation between Frailty Index and CD8⁺CD28⁺, r = 0.07222, or CD8⁻CD28⁻ , r = 0.07222. (c) CD8⁺ CD28 CD57 and the Frailty Index measuring the dominant hand. ***The difference in the two cell populations was significant: p < .0001; there was no significant correlation between Frailty Index and CD8⁺ CD57⁻ , r = 0.04129, or CD8⁻ CD57⁻ , r = 0.03515. (d) CD8⁺ CD57 cells and the Frailty Index measuring the dominant hand. ****The difference in the two cell populations was significant: p = <.0001; there was no significant correlation between Frailty Index and CD8⁺CD57⁺ , r = 0.0163, or CD8⁻CD57⁻ , r = 0.0163.
Results

Frailty measurements

Thirty-seven (37) HIV-positive patients compliant with ART therapy for years completed frailty testing. The demographic data is presented in Table 1. The average participant was 60.3 years old, male, and had <20 copies of HIV-1 RNA on the most recent viral load test, had taken ART for 15.8 years, had at least one past medical event (n = 33, 89%), and did not have major depression as measured by CES-D.

The majority of participants had FI scores that fell below 0.27, that is, were not frail (the average FI was 0.2 ± 0.1). The number of participants that fit the definition of frail using the dominant hand, non-dominant hand, and dual task tests were 7 (19%), 6 (16%), and 11 (30%), respectively. Table 2 shows the correlation between the FI using each of the three methods of measurement and several pertinent clinical variables. We found no statistically significant correlations between multiple independent health variables and the FI except for the number of medical problems when using the dominant hand, r = 0.34, p-value = 0.04. There were no statistically significant correlations between FI with either hand and the following: age, sex, last CD4 count, past medical event, AIDS diagnosis, and undetectable viral load. The seven frail patients (measuring dominant hand) did have an average of 3.1 prior medical problems (as defined in Methods) compared to the non-frail participants who had an average of 2.1 prior medical problems (Table 1).

For the CES-D score, there was a weak correlation with the number of past medical events (r = 0.35, p-value = 0.03) and moderate correlation with occurrence of past medical event(s) (r = 0.47, p-value = 0.003) (Table 3).

Immunologic measurements

We measured the surface expression of various HIV-1 and immune aging/exhaustion markers on CD4+ and CD8+ T-cells of the participants. For these results, we used FI as measured using the dominant hand (since there was no difference between hands; see above). The participants had a mean CD4 cell count of 732 and all were virally suppressed (Table 1). Although the CD4+ and CD8+ T-cell counts were significantly different, there was no correlation between their numbers and the FI (Figure 1(a)). Likewise, there was no correlation of the FI with the following four cell populations: CD8+ CD28+/− (Figure 1(b)), CD8+ CD28+/− CD57+/− (Figure 1(c)), CD8 CD57+/− (Figure 1(d)), CD4 CD57+/− (Figure 2(a)), and CD4 CD28+/− (Figure 2(b)). However, CD8+ cells did show a trend, although not significant, of TNF-α production in the unstimulated state indicating a low level of cytokine production by CD8+ cells (Figure 2(c)). There was no correlation with FI with CD4+ or CD8 IFN-γ production in
Discussion

We have been interested in the effect ART has upon “phenotypic or physical frailty” and “premature aging” of T-cells. One standard method of determining frailty measures physical parameters, whereas, another approach adds up cumulative deficits to arrive at a frailty score. We employed sensor-based technology to measure physical parameters of frailty. Although many investigators treat frailty occurring in the elderly and people living with HIV as identical processes, we believe “frailty” in these two populations is quite different. The characteristics of each cohort have been delineated. For example, in the community-dwelling elderly, frailty is age-related but it is not in people living with HIV. Prevalence of frailty in the community-dwelling elderly is ∼7%, whereas, it is much higher in people living with HIV, ∼20%, where it is often transient and reversible. Sarcopenia is a defining feature of frailty in the elderly but is not as important in people living with HIV where depression is a common factor. Following frail people living with HIV over time as we have done we find frailty to be highly fluid. Others have noted the same phenomenon. A recent study found that 36% of HIV-positive and age-matched uninfected control individuals changed frailty status between two consecutive visits. Nevertheless, the prevalent view assumes that the frailty occurring in community-dwelling elderly and in people living with HIV are similar or identical processes.

Table 1. Pertinent clinical factors for HIV-positive individuals in the study.

| Clinical factor | Value |
|----------------|-------|
| Age (mean ±SD) | 60.3±10.4 years |
| Greater than 50 years of age (n; %) | 34 (92) |
| Male (n) | 33 |
| Female (n) | 4 |
| Last CD4 count/mL (mean± SD) | 734.2 ± 338.9 |
| Last HIV-1 RNA <20 copies (n; %) | 33 (89) |
| Years on ART (mean± SD) | 15.8 ± 8.6 |
| History of prior AIDS diagnosis (n; %) | 19 (54) |
| History of other medical problems than HIV** (n; %) | 33 (89) |
| Number of other medical problems (mean ±SD) | 2.1 (1.3) |
| CES-D score*** (mean ±SD) | 16.1± 9.7 |
| FI*, dominant hand (mean ±SD) | 0.2 ± 0.1 |

*SD: standard deviation. **Occurrence of at least one medical problem: heart disease, lung disease, neurological disease, arthritis, cancer, surgery, hospitalization (2 days or more of hospitalization) in past year or any year (0 indicates no past medical event and 6 indicates all past medical events occurred). ***CES-D score ≥22 indicates the possibility of major depression; scores between 15 and 21 suggests moderate to mild depression; score <15 indicates no depression present in patient. FI: Frailty Index.

Table 2. Correlation co-efficient between Frailty Index and clinical factors.

| Clinical factors | Dominant hand | Non-dominant hand | Dual task |
|-----------------|---------------|-------------------|-----------|
| Age | 0.02 (0.92) | 0.21 (0.22) | 0.09 (0.58) |
| Sex (M/F) | -0.04 (0.83) | -0.17 (0.33) | 0.02 (0.91) |
| Last CD4 count | -0.26 (0.12) | -0.01 (0.96) | -0.12 (0.48) |
| Undetectable viral load (<20 copies/mL) | 0.09 (0.60) | -0.12 (0.50) | 0.04 (0.84) |
| Past medical problem | 0.22 (0.19) | 0.21 (0.22) | 0.18 (0.29) |
| Number of past medical problems | 0.34 (0.04) | 0.22 (0.18) | 0.27 (0.11) |
| Prior AIDS diagnosis | 0.01 (0.97) | -0.03 (0.88) | -0.08 (0.66) |
|***CES-D score | 0.04 (0.81) | -0.02 (0.93) | 0.13 (0.45) |

*Correlations greater than 0.7 or less than -0.7 indicate a strong linear relationship between the outcome and predictor. **p-values less than 0.05 are considered statistically significant. ***CES-D score ≥22 indicates the possibility of major depression; scores between 15 and 21 suggests moderate to mild depression; score <15 indicates no depression present in patient.
Table 3. Correlation between CES-D score and clinical factors.

| Clinical factor                  | *CES-D score | **p-value |
|---------------------------------|--------------|-----------|
| Age                             | 14           | 0.4       |
| Sex (male or female)            | 6            | 0.72      |
| Last CD4 count                  | 7            | 0.7       |
| Undetectable viral load (<20 copies/mL) | 25     | 0.15      |
| Number of past medical problems | 35           | 0.03      |
| Past medical problem (yes or no) | 47           | 0.003     |
| Prior AIDS diagnosis (yes or no)| 4            | 0.83      |

*CES-D score ≥22 indicates the possibility of major depression; scores between 15 and 21 suggest moderate to mild depression; score <15 indicates no depression present in patient. **p-values less than 0.05 are considered statistically significant.

Our study found results similar to those we have reported before. For example, seven of 37 HIV-positive subjects were frail, for a prevalence of 19% and the frailty status was not correlated with age, sex, the CD4+ cell count, being virally suppressed with ART, or whether they were diagnosed with AIDS in the past or were depressed (Table 2). The sole correlation with frailty we found was with the number of past medical problems (p=0.04). Past medical problems correlated with depression (p=0.003) (Table 3) and this relationship may explain the importance of depression in frail HIV-positive we noted before. We also found that frailty is often reversible with institution of ART and that ART over time protects against frailty.

It is claimed that immune aging or immunosenescence seen in HIV infection is similar to that which occurs in the uninfected elderly characterized by accumulation of highly differentiated immunocompetent cells with a concomitant reduction in hematopoietic progenitor and naive cells. In HIV-specific CD8+ T-cells, this population of highly differentiated cells expresses CD57 and loses their proliferative ability and undergoes apoptosis. These CD8 T-cells fall into 4 separate populations: CD28\^−CD57\^−, CD28\^−CD57\^+, CD28\^+CD57\^−, and CD28\^+CD57\^+. In our subjects, all of whom were virally suppressed, there was no correlation of the FI with any acknowledged T-cell marker of senescence including the absence of CD8\^−CD28\^+ or CD8\^−CD57\^+ cells. Although there was a residuum of TNF-α detected in some cells there was no correlation between TNF-α expression and the FI (Figure 2(d)). This residual TNF-α expression may occur in some of our treated patients with lower total CD4\^+ cell counts. Our work has demonstrated that long-term ART with higher CD4\^+ T-cell numbers improved patients immunologically, reducing HIV-specific CD8\^+ T-cell responses compared to those with lower CD4\^+ T-cell counts. In that same study, older people living with HIV exhibited decreasing levels of CD8\^+ T-cell responses with increasing age. Moreover, virologic control of HIV-positive patients on long-term ART was associated with a significant reduction in terminally differentiated T-cells demonstrating decreased cell senescence and improvement in numbers of naïve to memory T-cells. These studies showed a major improvement in the immunological markers associated with HIV-1 infection in older patients maintained on long-term ART.

**Conclusion**

We showed in this work that people living with HIV on long term, suppressive ART exhibit similar prevalence rates of frailty as our previous studies (i.e.,∼ 20%), but frailty did not correlate with age, sex, prior diagnosis of AIDS, or immunosenescence. Specifically, frailty did not correlate with any CD4\^− or CD8\^+ T-cell surface proteins known to be associated with immunosenescence such as is seen in frail, community-dwelling elderly individuals. The physical and immunological characteristics of frail, virally suppressed people living with HIV differed from that of frail, community-dwelling elderly. Thus, it is likely that the etiology of frailty in these two populations is different.

**Acknowledgments**

The authors express their gratitude to the patients for their participation in this study. SAK, NB, BN, and NA designed the study; CE and SNS collected clinical data and measured frailty; ML and NB collected samples and performed the immunological studies; SA and MM performed the statistics; ML made the figures and SAK wrote the draft; SAK, BN, and NA edited the final MS.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by intramural funds from the Petersen Clinic, University of Arizona and a grant to NA from the Arizona Biomedical Research Commission, Arizona Department of Health Services (ADHS14-082984).
ORCID iDs
Stephen A. Klotz  https://orcid.org/0000-0003-4488-4525
Bijan Najafi  https://orcid.org/0000-0002-0320-8101

References
1. Klotz SA. Jewel Box Biographies. Morrisville, NC: LuLu Press, 2013.
2. Desquibert L, Jacobson LP, Fried LP, et al. Multicenter AIDS Cohort Study. HIV-1 infection is associated with an earlier occurrence of a phenotype related to frailty. J Gerontol A Biol Sci Med Sci 2007 Nov; 62(11): 1279–1286. DOI: 10.1093/gerona/62.11.1279.
3. Effros RB, Fletcher CV, Gebo K, et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008 Aug 15; 47(4): 542PMC3130308. DOI: 10.1086/590150.
4. Thurn M and Gustafson DR. Faces of frailty in aging with HIV infection. Curr HIV/AIDS Rep 2017; 14(1): 31–37. DOI: 10.1007/s11904-017-0348-x.
5. Janas V, Berg E, Mohler MJ, et al. Antiretroviral therapy protects against frailty in HIV-1 infection. J Int Assoc Provid AIDS Care 2013 Jan-Feb; 12(1): 62–66. DOI: 10.1177/1545109712457241.
6. Walston JD and Fried LP. Frailty and its implications for care. In: Morrison R.S., and Meier D.E. (eds). Geriatric and Palliative Care. New York, NY: Oxford University Press; 2003, pp. 93–108.
7. Brenchley JM, Karandikar NJ, Betts MR, et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 2003 Apr 1; 101(7): 2711–2720. DOI: 10.1182/blood-2002-07-2103.
8. Boucher N, Dufeu-Duchesne T, Vicaut E, et al. CD28 expression in T cell aging and human longevity. Exp Gerontol 1998 May; 33(3): 267–282. DOI: 10.1016/S0531-5565(97)00132-0.
9. Erlandson KM, Ng DK, Jacobson LP, et al. Inflammation, Immune Activation, Immunosenescence, and Hormonal Biomarkers in the Frailty-Related Phenotype of Men With or at Risk for HIV Infection. J Infect Dis 2017 Jan 15; 215(2): 228–237. DOI: 10.1093/infdis/jiw523.
10. Herr M, Robine JM, Aegerter P, et al. Contribution of socioeconomic position over life to frailty differences in old age: comparison of life-course models in a French sample of 2350 old people. Ann Epidemiol 2015 Sep; 25(9): 674–680. DOI: 10.1016/j.annepidemiol.2015.05.006.
11. Behrens NE, Wertheimer A, Klotz SA, et al. Reduction in terminally differentiated T cells in virologically controlled HIV-infected aging patients on long-term antiretroviral therapy. PLoS One 2018 Jun 13; 13(6): e0199101. DOI: 10.1371/journal.pone.0199101.
12. Centers for Disease Control and Prevention. HIV Treatment as Prevention, 2021. https://cdc.gov (accessed 16 April 2021).
13. Behrens NE, Wertheimer A, Love MB, et al. Evaluation of HIV-specific T-cell responses in HIV-infected older patients with controlled viremia on long-term antiretroviral therapy. PLoS One 2020 Sep 17; 15(9): e0236320. DOI: 10.1371/journal.pone.0236320.
14. Behrens NE, Love M, Bandlamuri M, et al. Characterization of HIV-1 envelope V3 region sequences from virologically controlled HIV-infected older patients on long term antiretroviral therapy. AIDS Res Hum Retroviruses 2021 Mar; 37(3): 233–245. DOI: 10.1089/AID.2020.0139.
15. Toosizadeh N, Wendel C, Hsu CH, et al. Frailty assessment in older adults using upper-extremity function: index development. BMC Geriatr 2017 Jun 2; 17(1): 117PMC5457588. DOI: 10.1186/s12877-017-0509-1.
16. Toosizadeh N, Najafi B, Reiman EM, et al. Upper-extremity dual-task function: an innovative method to assess cognitive impairment in older adults. Front Aging Neurosci 2016; 8: 167. DOI: 10.3389/fragi.2016.00167.
17. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001; 56(3): M146–M156. DOI: 10.1093/gerona/56.3.m146.
18. Toosizadeh N, Joseph B, Heusser MR, et al. Assessing upper-extremity motion: an innovative, objective method to identify frailty in older bed-bound trauma patients. J Am Coll Surg 2016 Aug; 223(2): 240PMC4961594. DOI: 10.1016/j.jamcollsurg.2016.03.030.
19. Toosizadeh N, Mohler J and Najafi B. Assessing upper extremity motion: an innovative method to identify frailty. J Am Geriatr Soc 2015 Jun; 63(6): 1181PMC6635678. DOI: 10.1111/jgs.13451.
20. Radloff LS. The CES-D scale: a self report depression scale for research in the general population. Appl Psychol Meas 1977; 1: 385–401.
21. Cohen J. Set correlation and contingency tables. Appl Psych Meas 1988; 12: 425–434.
22. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ 2005 Aug 30; 173(5): 489–495. DOI: 10.1503/cmaj.050051.
23. Klotz SA and Mohler MJ. Contemporary HIV patients and the frailty syndrome. Austin J Infect Dis 2014; (12): 2.
24. Rees HC, Meister E, Mohler MJ, et al. HIV-related frailty is not characterized by sarcopenia. J Int Assoc Provid AIDS Care 2016 Mar-Apr; 15(2): 131–134. DOI: 10.1177/2325974114553848.
25. Verheij E, Wit FW, Verhoeket SO, et al. Frequency, risk factors, and mediators of frailty transitions during long-term follow-up among people with HIV and HIV-negative AEGhIV cohort participants. J Acquir Immune Defic Syndr 2020 Oct 16; 86: 110–118. doi: 10.1097/QAI.0000000000002532.
26. Edwards A, Siedner MJ, Nash S, et al. HIV serostatus, inflammatory biomarkers and the frailty phenotype among older people in rural KwaZulu-Natal, South Africa. Afr J AIDS Res 2020 Sep; 19(3): 177–185. DOI: 10.2989/16085906.2020.1790398.
27. Appay V and Sauce D. Assessing immune aging in HIV-infected patients. Virulence 2017 Jul 4; 8(5): 529PMC5538339. DOI: 10.1080/21505594.2016.1195536.
28. Pangrazzi L and Weinberger B. T cells, aging and senescence. Exp Gerontol 2020 Feb 22; 134: 110887. DOI: 10.1016/j.exger.2020.110887.
29. Pangrazzi L, Reidla J, Carmona Arana JA, et al. CD28 and CD57 define four populations with distinct phenotypic properties within human CD8+ T cells. Eur J Immunol 2020 Mar; 50(3): 363–379. DOI: 10.1002/eji.201948362.
30. Lederman MM, Funderburg NT, Sekaly RP, et al. Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol 2013; 119: 51PMC4126613. DOI: 10.1016/B978-0-12-407707-2.00002-3.